HUISARTS EN WETENSCHAP Content Navigatie Servicelinks Zoeken
Blader huidige nummer

Blader huidige nummer

homeNHG: standaard

NHG: standaard

NHG-standaard Het spiraaltje

Tweede herziening

Huisarts en Wetenschap, jaargang 2009, nummer 2:79-90

Huisarts en Wetenschap jaargang 52, nummer 2 (2008) p. 79-90 Zie voor de tekst van NHG-Standaard de NHG-website: www.nhg.org.

  1. 1. Bij verwijzingen naar NHG-producten: zie www.nhg.org.
  2. 2. Anonymus. FFPRHC Guidance (April 2006). Emergency contraception. J Fam Plann Reprod Health Care 2006;32:121-8.
  3. 3. Anonymus. FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 2005;31:139-51.
  4. 4. Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-7.
  5. 5. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
  6. 6. Andersson K, Ryde-Blomqvist E, Lindell K, Odlind V, Milsom I. Perforations with intrauterine devices. Report from a Swedish survey. Contraception 1998;57:251-5.
  7. 7. Anonymus. IUD's, a new look. Population Reports B-5, 1. Baltimore: Johns Hopkins University, 1988.
  8. 8. Backman T. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf 2004;27:1185-204.
  9. 9. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000;107:335-9.
  10. 10. Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990;42:51-66.
  11. 11. Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 1995;11:85-95.
  12. 12. Baveja R, Bichille LK, Coyaji KJ, Engineer AD, Gogoi MP, Hazra MN et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception 1989;39:37-52.
  13. 13. Baxter K. Stockley's drug interactions. A source book of interactions, their mechanisms, clinical importance and management. 8 ed. London/Chigaco: Pharmaceutical Press, 2008.
  14. 14. Belhadj H, Sivin I, Diaz S, Pavez M, Tejada AS, Brache V et al. Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device. Contraception 1986;34:261-7.
  15. 15. Bilian X. Intrauterine devices. Best Pract Res Clin Obstet Gynaecol 2002;16:155-68.
  16. 16. Bonacho I, Pita S, Gomez-Besteiro MI. The importance of the removal of the intrauterine device in genital colonization by actinomyces. Gynecol Obstet Invest 2001;52:119-23.
  17. 17. Caliskan E, Ozturk N, Dilbaz BO, Dilbaz S. Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur J Contracept Reprod Health Care 2003;8:150-5.
  18. 18. CBG-MEB. Geneesmiddeleninformatiebank (2008). http://www.cbg-meb.nl/CBG/nl/people/geneesmiddeleninformatiebank/default.htm .
  19. 19. Chatwani A, Amin HS. Incidence of actinomyces associated with intrauterine devices. J Reprod Med 1994;39:585-7.
  20. 20. Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev 2004;CD001324.
  21. 21. Chi I. What we have learned from recent IUD studies: a researcher's perspective. Contraception 1993;48:81-108.
  22. 22. Commissie Farmaceutische Hulp. Farmacotherapeutisch Kompas 2008. Amstelveen: College voor zorgverzekeringen, 2008.
  23. 23. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002;28:73-7.
  24. 24. De Graaf L. Meldingen aan Lareb over mogelijke systemische effecten bij gebruik van het hormoon bevattende IUD Mirena. Tijdschr Huisartsgeneeskd 2002;4:134-7.
  25. 25. De Groot M. Mirena en uterusperforatie. Huisarts Wet 2005;48:165-6.
  26. 26. De Kroon CD, Van Houwelingen JC, Trimbos JB, Jansen FW. The value of transvaginal ultrasound to monitor the position of an intrauterine device after insertion. A technology assessment study. Hum Reprod 2003;18:2323-7.
  27. 27. Diaz J, Bahamondes L, Diaz M, Marchi N, Faundes A, Marini M. Evaluation of the performance of the copper T380A IUD up to ten years. Is this IUD a reversible but potentially permanent method? Adv Contracept 1992;8:275-80.
  28. 28. Ely JW, Kennedy CM, Clark EC, Bowdler NC. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med 2006;19:590-602.
  29. 29. Eroglu K, Akkuzu G, Vural G, Dilbaz B, Akin A, Taskin L et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception 2006;74:376-81.
  30. 30. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8.
  31. 31. Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted? J Fam Plann Reprod Health Care 2003;29:227-31.
  32. 32. Faundes A, Telles E, Cristofoletti ML, Faundes D, Castro S, Hardy E. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception 1998;58:105-9.
  33. 33. Faundes D, Perdigao A, Faundes A, Bahamondes L, Petta CA. T-shaped IUDs accommodate in their position during the first 3 months after insertion. Contraception 2000;62:165-8.
  34. 34. Ferraz do Lago R, Simoes JA, Bahamondes L, Camargo RP, Perrotti M, Monteiro I. Follow-up of users of intrauterine device with and without bacterial vaginosis and other cervicovaginal infections. Contraception 2003;68:105-9.
  35. 35. French R, Van Vliet H, Cowan F, Mansour D, Morris S, Hughes D et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2004;CD001776.
  36. 36. French RS, Cowan FM, Mansour D, Higgins JP, Robinson A, Procter T et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. BJOG 2000;107:1218-25.
  37. 37. Gareen IF. Intrauterine devices and pelvic inflammatory disease. Curr Womens Health Rep 2003;3:280-7.
  38. 38. Garland SM, Rawling D. Pelvic actinomycosis in association with an intrauterine device. Aust N Z J Obstet Gynaecol 1993;33:96-8.
  39. 39. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2004;CD001777.
  40. 40. Grimes D, Schulz K, Van Vliet H, Stanwood N. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev 2001;CD003036.
  41. 41. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013-9.
  42. 42. Grimes DA, Schulz KF. Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. Contraception 1999;60:57-63.
  43. 43. Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception 2003;67:53-6.
  44. 44. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999;4:67-73.
  45. 45. Hodoglugil NN, Aslan D, Bertan M. Intrauterine device use and some issues related to sexually transmitted disease screening and occurrence. Contraception 2000;61:359-64.
  46. 46. Hubacher D, Reyes V, Lillo S, Zepeda A, Chen PL, Croxatto H. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol 2006;195:1272-7.
  47. 47. Inki P, Hurskainen R, Palo P, Ekholm E, Grenman S, Kivela A et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol 2002;20:381-5.
  48. 48. Jensen HH, Blaabjerg J, Lyndrup J. Profylaktisk brug af prostaglandinsynthesehaemmere ved oplaegning af spiral. Ugeskr Laeger 1998;160:6958-61.
  49. 49. Kalaichelvan V, Maw AA, Singh K. Actinomyces in cervical smears of women using the intrauterine device in Singapore. Contraception 2006;73:352-5.
  50. 50. Kelsey JJ. Hormonal contraception and lactation. J Hum Lact 1996;12:315-8.
  51. 51. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. Informatorium Medicamentorum. Den Haag: KNMP, 2008.
  52. 52. Kulier R, O'Brien PA, Helmerhorst FM, Usher-Patel M, d'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev 2007;CD005347.
  53. 53. Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 1999;180:265-9.
  54. 54. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001;19:355-63.
  55. 55. Merki-Feld GS, Lebeda E, Hogg B, Keller PJ. The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper- and levonorgestrel-releasing intrauterine devices. Contraception 2000;61:365-8.
  56. 56. Milsom I, Andersson K, Jonasson K, Lindstedt G, Rybo G. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception 1995;52:175-9.
  57. 57. Muller-Holzner E, Ruth NR, Abfalter E, Schrocksnadel H, Dapunt O, Martin-Sances L et al. IUD-associated pelvic actinomycosis: a report of five cases. Int J Gynecol Pathol 1995;14:70-4.
  58. 58. Murty J. Use and effectiveness of oral analgesia when fitting an intrauterine device. J Fam Plann Reprod Health Care 2003;29:150-1.
  59. 59. Nederlandse Hartstichting. Preventie bacteriële endocarditis. Een advies van de endocardititis profylaxe commissie [brochure verschijnt in november 2008]. Den Haag: Nederlandse Hartstichting, 2008.
  60. 60. Newton J, Tacchi D. Long-term use of copper intrauterine devices. A statement from the Medical Advisory Committee of the Family Planning Association and the National Association of Family Planning Doctors. Lancet 1990;335:1322-3.
  61. 61. NICE. Long-acting reversible contraception; the effect and approprate use of long-acting reversible contraception (2005). RCOG Press. http://www.nice.org.uk/nicemedia/pdf/CG030fullguideline.pdf .
  62. 62. NVOG. Richtlijnen (Uro-)gynaecologie. http://nvog-documenten.nl/index.php?pagina=/richtlijn/pagina.php&fSelectTG_62=75&fSelectedSub=62&fSelectedParent=75 .
  63. 63. O'Brien PA, Marfleet C. Frameless versus classical intrauterine device for contraception. Cochrane Database Syst Rev 2005;CD003282.
  64. 64. Penney G, Brechin S, De Souza A, Bankowska U, Belfield T, Gormley M et al. FFPRHC Guidance (January 2004). The copper intrauterine device as long-term contraception. J Fam Plann Reprod Health Care 2004;30:29-41.
  65. 65. Penney G, Brechin S, Glasier A. Family planning masterclass: evidence-based answers to 1000 questions. London: RCOG Press, 2006.
  66. 66. Schaefer C, Peters P, Miller RK. Drugs during pregnancy and lactation. Treatment options and risk assessment. 2nd ed. Amsterdam: Elsevier Gezondheidszorg, 2007.
  67. 67. Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005;72:346-51.
  68. 68. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291-8.
  69. 69. Sivin I, El Mahgoub S, McCarthy T, Mishell DR, Jr., Shoupe D, Alvarez F et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 1990;42:361-78.
  70. 70. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 ug/d and the Copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. Fertil Steril 1994;61:70-7.
  71. 71. Skjeldestad FE. How effectively do copper intrauterine devices prevent ectopic pregnancy? Acta Obstet Gynecol Scand 1997;76:684-90.
  72. 72. Steen R, Shapiro K. Intrauterine contraceptive devices and risk of pelvic inflammatory disease: standard of care in high STI prevalence settings. Reprod Health Matters 2004;12:136-43.
  73. 73. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004;69:407-12.
  74. 74. Tacchi D. Long-term use of copper intrauterine devices (letter). Lancet 1990;182.
  75. 75. Tolcher R. Intrauterine techniques: contentious or consensus opinion? J Fam Plann Reprod Health Care 2003;29:21-4.
  76. 76. Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en verrichtingen in de huisartspraktijk: klachten en aandoeningen in de bevolking en in de huisartspraktijk. Bilthoven: RIVM, 2004. Utrecht/Bilthoven: NIVEL/RIVM, 2004.
  77. 77. Van Houdenhoven K., Van Kaam KJ, Van Grootheest AC, Salemans TH, Dunselman GA. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception 2006;73:257-60.
  78. 78. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006;125:9-28.
  79. 79. Vasilakis C, Jick H, Del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999;354:1610-1.
  80. 80. Westrom L, Bengtsson LP, Mardh PA. Incidence, trends, and risks of ectopic pregnancy in a population of women. Br Med J (Clin Res Ed) 1981;282:15-8.
  81. 81. WHO. Medical eligibility criteria for contraceptive use (2004). http://www.who.int/reproductive-health/publications/mec/mec/pdf .
  82. 82. WHO. Selected practice recommendations for contraceptive use (2004). http://www.who.int/reproductive-health/publications/spr/spr.pdf .
  83. 83. Zhou L, Harrison-Woolrych M, Coulter DM. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol Drug Saf 2003;12:371-7.
Reacties

lees alle reacties (totaal 0) »

Dit artikel:

Interactief

  • Reageer
  • Lees reacties
  • Stuur door
  • Bewaar
  • Print
  • Mail mij de reacties
  • Voeg artikel toe aan:

Zoeken

Zoek binnen: Uitgebreid zoeken

Inloggen
Wachtwoord vergeten?

Abonneren

Meest gelezen

Meer artikelen »
 

Medisch nieuws

Meer Medisch nieuws »
 

Nederlands Huisartsen Genootschap

 

Navigatie

Service

nederlands huisartsen genootschap Bohn Stafleu van Loghum

Copyright © 2012 Bohn Stafleu van Loghum. All rights reserved.